Millennium Management
KYTX icon

Millennium Management’s Kyverna Therapeutics KYTX Stock Holding History

Millennium Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.68M Buy
1,005,508
+412,139
+69% +$3.43M ﹤0.01% 2308
2025
Q4 		$5.58M Buy
593,369
+41,734
+8% +$310K ﹤0.01% 2889
2025
Q3 		$3.31M Buy
551,635
+99,075
+22% +$396K ﹤0.01% 3550
2025
Q2 		$1.39M Buy
452,560
+214,321
+90% +$530K ﹤0.01% 4182
2025
Q1 		$460K Sell
238,239
-508,282
-68% -$1.5M ﹤0.01% 4867
2024
Q4 		$2.79M Sell
746,521
-507,035
-40% -$2.43M ﹤0.01% 3371
2024
Q3 		$6.13M Buy
1,253,556
+330,474
+36% +$2.55M ﹤0.01% 2664
2024
Q2 		$6.92M Buy
923,082
+227,988
+33% +$3.48M ﹤0.01% 2404
2024
Q1 		$17.3M Buy
+695,094
New +$19.4M 0.01% 1682

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management's KYTX Position: Q1 2026 in Review

Millennium Management increased its Kyverna Therapeutics (KYTX) stake by 69% in Q1 2026, buying an estimated $3.43M and bringing the position to 1,005,508 shares worth $8.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2308.

Millennium Management first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $17.3M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Millennium Management held 1,005,508 shares of Kyverna Therapeutics worth $8.68M as of Q1 2026.
  • Millennium Management bought 412,139 Kyverna Therapeutics shares in Q1 2026, an estimated $3.43M.
  • Kyverna Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2308 holding.
  • Millennium Management first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Millennium Management's Kyverna Therapeutics position peaked at $17.3M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.